Study study type PathologyT1T0Patientssample sizesROB Results

la/mBC - HR positive - L1 - PIK3CA mutant breast cancer - HR positive la/mBC - HR positive la/mBC - HR-positive - 1st line (L1) la/mBC - HR positive - L1 - PIK3CA mutant

versus paclitaxel
ipatasertib plus paclitaxel
IPATunity130, 2022
  NCT03337724
RCTla/mBC - HR positive - L1 - PIK3CA mutantipatasertib plus paclitaxelplacebo plus paclitaxelPatients with HR-positive and HER2-negative PIK3CA/AKT1/PTEN-altered measurable advanced breast cancer146 / 76low
inconclusive
  • inconclusive 0 % increase in progression or deaths (PFS) (PE)